2.705 USD
+0.04 (+1.69%)
2.705 USD
0 (0%)
Taking everything into account, BTMD scores 5 out of 10 in our fundamental rating. BTMD was compared to 192 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. BTMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year BTMD was profitable.
In the past year BTMD had a positive cash flow from operations.
Of the past 5 years BTMD 4 years were profitable.
BTMD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BTMD's Return On Assets of 25.87% is amongst the best of the industry. BTMD outperforms 98.44% of its industry peers.
BTMD has a better Return On Invested Capital (45.22%) than 99.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROIC | 45.22% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 14.72%, BTMD belongs to the best of the industry, outperforming 86.98% of the companies in the same industry.
BTMD's Profit Margin has declined in the last couple of years.
BTMD has a Operating Margin of 16.09%. This is amongst the best in the industry. BTMD outperforms 85.42% of its industry peers.
In the last couple of years the Operating Margin of BTMD has declined.
Looking at the Gross Margin, with a value of 72.23%, BTMD is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
Compared to 1 year ago, BTMD has less shares outstanding
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
BTMD has an Altman-Z score of 2.30. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.30, BTMD is doing good in the industry, outperforming 62.50% of the companies in the same industry.
BTMD has a debt to FCF ratio of 4.18. This is a neutral value as BTMD would need 4.18 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 4.18, BTMD belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Altman-Z | 2.3 |
ROIC/WACC4.99
WACC9.07%
2.3 Liquidity
A Current Ratio of 1.01 indicates that BTMD should not have too much problems paying its short term obligations.
With a Current ratio value of 1.01, BTMD is not doing good in the industry: 81.77% of the companies in the same industry are doing better.
BTMD has a Quick Ratio of 1.01. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD's Quick ratio of 0.72 is on the low side compared to the rest of the industry. BTMD is outperformed by 86.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 190.00% over the past year.
The earnings per share for BTMD have been decreasing by -48.53% on average. This is quite bad
BTMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.44%.
The Revenue has been growing by 12.38% on average over the past years. This is quite good.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
3.2 Future
BTMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.
BTMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.89% yearly.
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y41.42%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.89%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 3.11 indicates a rather cheap valuation of BTMD.
97.92% of the companies in the same industry are more expensive than BTMD, based on the Price/Earnings ratio.
BTMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.31.
Based on the Price/Forward Earnings ratio of 7.88, the valuation of BTMD can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 91.67% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of BTMD to the average of the S&P500 Index (36.56), we can say BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.11 | ||
| Fwd PE | 7.88 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 93.23% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 98.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.59 | ||
| EV/EBITDA | 6.77 |
4.3 Compensation for Growth
BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
BTMD's earnings are expected to grow with 24.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y24.94%
EPS Next 3Y24.88%
5. Dividend
5.1 Amount
No dividends for BTMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.705
+0.04 (+1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners64.32%
Inst Owner Change-8.25%
Ins Owners9.75%
Ins Owner Change0%
Market Cap123.51M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target5.2 (92.24%)
Short Float %3.35%
Short Ratio7.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.74%
PT rev (3m)-5.74%
EPS NQ rev (1m)14.7%
EPS NQ rev (3m)14.7%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-2.82%
Revenue NQ rev (3m)-2.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.11 | ||
| Fwd PE | 7.88 | ||
| P/S | 0.63 | ||
| P/FCF | 3.59 | ||
| P/OCF | 3.09 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.77 |
EPS(TTM)0.87
EY32.16%
EPS(NY)0.34
Fwd EY12.7%
FCF(TTM)0.75
FCFY27.86%
OCF(TTM)0.88
OCFY32.38%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)0.02
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROCE | 57.24% | ||
| ROIC | 45.22% | ||
| ROICexc | 92.24% | ||
| ROICexgc | 190.38% | ||
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% | ||
| FCFM | 17.59% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Debt/EBITDA | 3.02 | ||
| Cap/Depr | 144.67% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 3.81 | ||
| Cash Conversion | 113.15% | ||
| Profit Quality | 119.51% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 2.3 |
F-Score7
WACC9.07%
ROIC/WACC4.99
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y41.42%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.89%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year32.82%
EBIT Next 3Y16.27%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%
BIOTE CORP -A / BTMD FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
What is the valuation status of BIOTE CORP -A (BTMD) stock?
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
What is the expected EPS growth for BIOTE CORP -A (BTMD) stock?
The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to grow by 166.59% in the next year.
Can you provide the dividend sustainability for BTMD stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.